Reducing diabetes medication costs can help improve outcomes, especially for low-income patients


This article has been reviewed according to Science X’s editorial process
and policies.
Editors have highlighted the following attributes while ensuring the content’s credibility:

fact-checked

peer-reviewed publication

trusted source

proofread


Credit: CC0 Public Domain

× close


Credit: CC0 Public Domain

A new study led by researchers at the Harvard Pilgrim Health Care Institute has found that reducing out-of-pocket costs for patients with diabetes, especially those considered low-income, can be one step toward improving health outcomes.

The study, “Acute Diabetes Complications After Transition to a Value-Based Medication Benefit,” is published in JAMA Health Forum.

Treatment with antidiabetic agents, antihypertensives, and lipid-lowering drugs is essential for decreasing acute, preventable complications, including bacterial infections, neurovascular events, acute coronary disease, and diabetic ketoacidosis. However, high for these medications can lead to suboptimal use.

To help alleviate these cost barriers, some employers have added preventive drug lists (PDL) to their insurance plan offerings. PDLs allow enrollees to pay reduced out-of-pocket amounts for a range of high-value preventive medications, including . While available evidence has shown that PDLs are associated with increased preventive medication prescription fills among patients with diabetes living in lower-income neighborhoods, the effects on health outcomes have been unclear.

“Employers are increasingly adopting PDLs to improve the health of their workers,” said lead author Frank Wharam, Harvard Medical School visiting professor of population medicine at the Harvard Pilgrim Health Care Institute and professor of medicine at Duke University.

“Despite the growing prevalence of PDLs, their effect on health has been unclear until now. Our study is the first to suggest that PDLs can improve health outcomes among people with diabetes.”

Using a population of national commercial health plan members with diabetes aged 12 to 64, the team analyzed acute, preventable diabetes complications among members whose employers adopted PDLs compared to members whose employers did not adopt PDLs.

The team found that following a switch to a plan including a PDL, members increased their use of antidiabetic medications, while days of acute, preventable diabetes complications decreased by 8.4% in the overall PDL group. Preventable days of diabetes complications decreased by 10.2% among PDL members from lower-income areas compared to the control group.

“We were pleased to discover that a relatively straightforward intervention was associated with improved among diabetes patients, especially lower-income ones who might struggle with costs,” said senior author Dennis Ross-Degnan, Harvard Medical School associate professor of population medicine at the Harvard Pilgrim Health Care Institute.

He added, “Future studies should determine whether PDLs might also benefit patients with other who are also at risk for adherence-related complications.”

More information:
Acute Diabetes Complications After Transition to a Value-Based Medication Benefit, JAMA Health Forum (2024). DOI: 10.1001/jamahealthforum.2023.5309

Journal information:
JAMA Health Forum




Source link

girlfriends having fun with their favorite toy.amateur girls double dong full insertion.
pornsnake.net
sex tube my golden pussy is not beautiful and.